Fetching the paper…
Reading the bibliography…
Drug combinations play an important role in therapeutics due to its better efficacy and reduced toxicity.
Die quantitativen probleme der pharmakologie
S Loewe · 1928
Earlier work this paper cites.
The toxicity of poisons applied jointly 1
Chester I Bliss · 1939
Earlier work this paper cites.
Aids antiviral screen data
National Cancer Institute (NCI) · 2004
Earlier work this paper cites.
Systematic identification of synergistic drug pairs targeting hiv
Xu Tan, Long Hu, Lovelace J Luquette, Geng Gao, Yifang Liu, Hongjing Qu, Ruibin Xi, Zhi John Lu, Peter J Park, and Stephen J Elledge · 2012
Earlier work this paper cites.
Convolutional networks on graphs for learning molecular fingerprints
David K Duvenaud, Dougal Maclaurin, Jorge Iparraguirre, Rafael Bombarell, Timothy Hirzel, Alán Aspuru-Guzik, and Ryan P Adams · 2015
Earlier work this paper cites.
An unbiased oncology compound screen to identify novel combination strategies
Jennifer O’Neil, Yair Benita, Igor Feldman, Melissa Chenard, Brian Roberts, Yaping Liu, Jing Li, Astrid Kral, Serguei Lejnine, Andrey Loboda, et al · 2016
Earlier work this paper cites.
The chembl database in 2017
Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez, Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibrián-Uhalte, et al · 2017
Earlier work this paper cites.
Neural message passing for quantum chemistry
Justin Gilmer, Samuel S Schoenholz, Patrick F Riley, Oriol Vinyals, and George E Dahl · 2017
Earlier work this paper cites.
The national cancer institute almanac: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity
Susan L Holbeck, Richard Camalier, James A Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, et al · 2017
Cited alongside, same era.
Deepsynergy: predicting anti-cancer drug synergy with deep learning
Kristina Preuer, Richard PI Lewis, Sepp Hochreiter, Andreas Bender, Krishna C Bulusu, and Günter Klambauer · 2018
Cited alongside, same era.
Predicting tumor cell line response to drug pairs with deep learning
Fangfang Xia, Maulik Shukla, Thomas Brettin, Cristina Garcia-Cardona, Judith Cohn, Jonathan E Allen, Sergei Maslov, Susan L Holbeck, James H Doroshow, Yvonne A Evrard, et al · 2018
Cited alongside, same era.
Network-based prediction of drug combinations
Feixiong Cheng, István A Kovács, and Albert-László Barabási · 2019
Cited alongside, same era.
Predicting synergism of cancer drug combinations using nci-almanac data
Pavel Sidorov, Stefan Naulaerts, Jérémy Ariey-Bonnet, Eddy Pasquier, and Pedro Ballester · 2019
Sars-cov-2 plpro inhibitor assay
Meredith Davis-Gardner · 2020
Closest in time.
Identification of inhibitors of sars-cov-2 in-vitro cellular toxicity in human (caco-2) cells using a large scale drug repurposing collection
Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, et al · 2020
Closest in time.
A sars-cov-2 protein interaction map reveals targets for drug repurposing
David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O’Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al · 2020
Closest in time.
Network medicine framework for identifying drug repurposing opportunities for covid-19
Deisy Morselli Gysi, Ítalo Do Valle, Marinka Zitnik, Asher Ameli, Xiao Gan, Onur Varol, Helia Sanchez, Rebecca Marlene Baron, Dina Ghiassian, Joseph Loscalzo, et al · 2020
Closest in time.
Sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor
alphaXiv searches the wider corpus for related work and actual follow-ups.
alphaXiv is searching for related work…
Cited alongside, same era.
Analyzing learned molecular representations for property prediction
Kevin Yang, Kyle Swanson, Wengong Jin, Connor Coley, Philipp Eiden, Hua Gao, Angel Guzman-Perez, Timothy Hopper, Brian Kelley, Miriam Mathea, et al · 2019
Cited alongside, same era.
Design of high-order antibiotic combinations against m. tuberculosis by ranking and exclusion
Kaan Yilancioglu and Murat Cokol · 2019
Cited alongside, same era.
Discovery of synergistic and antagonistic drug combinations against sars-cov-2 in vitro
Tesia Bobrowski, Lu Chen, Rich T Eastman, Zina Itkin, Paul Shinn, Catherine Chen, Hui Guo, Wei Zheng, Sam Michael, Anton Simeonov, et al · 2020
Cited alongside, same era.
Sars-cov-2 3cl protease enzymatic activity
National Center for Advancing Translational Sciences (NCATS)
Cited in the paper.
Ace2 enzymatic activity
National Center for Advancing Translational Sciences (NCATS)
Cited in the paper.
Sars-cov-2 cytopathic effect (cpe) screening
National Center for Advancing Translational Sciences (NCATS)
Cited in the paper.
In vitro sars-cov-2 evaluation of drug combinations for exploring chemical biology and potential therapeutic use
National Center for Advancing Translational Sciences (NCATS)
Cited in the paper.
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, et al · 2020
Closest in time.
Adaptive invariance for molecule property prediction
Wengong Jin, Regina Barzilay, and Tommi Jaakkola · 2020
Closest in time.
Discovery of sars-cov-2 antiviral drugs through large-scale compound repurposing
Laura Riva, Shuofeng Yuan, Xin Yin, Laura Martin-Sancho, Naoko Matsunaga, Lars Pache, Sebastian Burgstaller-Muehlbacher, Paul D De Jesus, Peter Teriete, Mitchell V Hull, et al · 2020
Closest in time.
Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2
Yadi Zhou, Yuan Hou, Jiayu Shen, Yin Huang, William Martin, and Feixiong Cheng · 2020
Closest in time.